Full Product Specifications
| Specification |
Detail |
| Also Known As |
LY3298176 / GLP TZ / Dual GIP and GLP-1 Agonist |
| CAS Number |
2023788-19-2 |
| Molecular Formula |
C225H348N48O68 |
| Molecular Weight |
~4,813 Da |
| Sequence Length |
39 amino acids |
| Vial Size |
120mg per vial |
| Form |
White lyophilized powder |
| Purity — this batch |
99.97% — Freedom Diagnostics verified |
| Net Peptide Content |
119.25mg confirmed (accounts for salt form and counter-ion mass) |
| Testing Method |
HPLC with UV detection coupled with mass spectrometry (LC-MS) |
| Lot Number |
TIR120-06162026 |
| COA Accession |
2607230404 — publicly verifiable at FreedomDiagnosticsTesting.com |
| Receptor Targets |
GLP-1R / GIPR (dual agonist) |
| Half-life |
~120 hours (~5 days) in relevant research models |
| Cost Per Milligram |
~$2.89/mg at single vial price |
| Recommended Reconstitution |
6 to 12mL BAC water for 10 to 20mg/mL working concentrations |
| Long-term storage |
-20°C, sealed vial, up to 24 months |
| Short-term storage |
4°C, use within 28 days of reconstitution |
| Reconstitution solvent |
Bacteriostatic water (BAC water) recommended |
| Intended Use |
In vitro laboratory research only — not for human use |
| Regulatory Status |
FDA approved as Mounjaro (T2D) and Zepbound (obesity). This product is RUO only. |
Certificate of Analysis — Freedom Diagnostics
Freedom Diagnostics tested this batch independently. The 99.97% result is publicly searchable at FreedomDiagnosticsTesting.com using accession 2607230404. No contact with Profound Peptides is needed to verify it.
| COA Field |
Detail |
| PURITY RESULT |
99.97% |
| TESTING LAB |
Freedom Diagnostics (USA) |
| LOT NUMBER |
TIR120-06162026 |
| COA / ACCESSION |
2607230404 |
| SEARCH CODE |
Prof2607230404 |
| TESTING METHOD |
HPLC with UV detection coupled with mass spectrometry (LC-MS) |
| NET PEPTIDE CONTENT |
119.25mg confirmed |
| IDENTITY |
Confirmed / GLP TZ |
| APPEARANCE |
White lyophilized powder |
| RECEIVED DATE |
07/23/2026 |
| REPORT DATE |
07/27/2026 |
| PRINCIPAL CHEMIST |
Alex Johnson |
Download COA PDF
Tirzepatide RUO 120mg is for labs that have a confirmed protocol and need enough dual agonist stock to run it without reordering. At 6mL of bacteriostatic water, the 119.25mg confirmed net content gives a 20mg/mL working stock. At 12mL, you get 10mg/mL. Either way, a single vial covers multi-arm rodent metabolic studies, extended MASLD or T2D models, and head-to-head receptor comparison assays against GLP-1 monoagonists or triple agonists without touching a second batch.
Tirzepatide has the most extensive published research base of any dual agonist in the GLP-1 class. As of 2026 that includes:
FDA approval for Type 2 Diabetes (Mounjaro) and obesity (Zepbound)
SURPASS-CVOT cardiovascular outcomes data published in NEJM (December 2025)
SURMOUNT-5 head-to-head superiority data versus Semaglutide (NEJM, July 2025)
Ongoing trials for MASLD (Phase 2b SYNERGY-NASH), chronic kidney disease (Phase 2 TREASURE-CKD), and obesity-related mortality (Phase 3 SURMOUNT-MMO)
The 120mg RUO format suits any lab that needs a well-characterized dual agonist reference compound with a deep clinical literature base. All use is in vitro or preclinical only. Not for human administration.
Reviews
There are no reviews yet.